Sexual disparities in the incidence and course of SLE and RA

Clinical Immunology

Volumn 149, Issue 2, 2013, Pages 211-218

  Tedeschi, Sara K ^a   Bermas, Bonnie ^a   Costenbader, Karen H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Rheumatoid arthritis; Sex differences; Systemic lupus erythematosus

Indexed keywords

CD40 LIGAND; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROLACTIN; SEX HORMONE; TOLL LIKE RECEPTOR 7;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; COMORBIDITY; DISEASE ACTIVITY; GENOTYPE; HEREDITY; HORMONE SUBSTITUTION; HUMAN; IMMUNE SYSTEM; INCIDENCE; INFERTILITY THERAPY; KLINEFELTER SYNDROME; PREGNANCY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; X CHROMOSOME;

EID: 84885954878     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.03.003     Document Type: Review

References (94)

1. Shlomchik M.J., Craft J.E., Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 2001, 1(2):147-153.
2. Wilder R.L. Hormones, pregnancy, and autoimmune diseases. Ann. N. Y. Acad. Sci. 1998, 840:45-50.
3. Cutolo M. Sex hormone adjuvant therapy in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 2000, 26(4):881-895.
4. Cutolo M., et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004, 13(9):635-638.
5. Hughes G.C. Progesterone and autoimmune disease. Autoimmun. Rev. 2012, 11(6-7):A502-A514.
6. Weckerle C.E., Niewold T.B. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin. Rev. Allergy Immunol. 2011, 40(1):42-49.
7. Grimaldi C.M., et al. Hormonal modulation of B cell development and repertoire selection. Mol. Immunol. 2005, 42(7):811-820.
8. Lahita R.G. The role of sex hormones in systemic lupus erythematosus. Curr. Opin. Rheumatol. 1999, 11(5):352-356.
9. Pennell L.M., Galligan C.L., Fish E.N. Sex affects immunity. J. Autoimmun. 2012, 38(2-3):J282-J291.
10. Petri M. Sex hormones and systemic lupus erythematosus. Lupus 2008, 17(5):412-415.
11. Wilder R.L. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J. Rheumatol. Suppl. 1996, 44:10-12.
12. Cohen-Solal J.F., et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 2008, 17(6):528-532.
13. Waite J.C., Skokos D. Th17 response and inflammatory autoimmune diseases. Int. J. Inflamm. 2012, 2012:819467.
14. Shelly S., Boaz M., Orbach H. Prolactin and autoimmunity. Autoimmun. Rev. 2012, 11(6-7):A465-A470.
15. Ballou S.P., Khan M.A., Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum. 1982, 25(1):55-60.
16. Lu L.J., et al. Review: male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010, 19(2):119-129.
17. Mohan C. Environment versus genetics in autoimmunity: a geneticist's perspective. Lupus 2006, 15(11):791-793.
18. Sanchez-Guerrero J., et al. Hair dye use and the risk of developing systemic lupus erythematosus. Arthritis Rheum. 1996, 39(4):657-662.
19. Wang J., et al. Is lipstick associated with the development of systemic lupus erythematosus (SLE)?. Clin. Rheumatol. 2008, 27(9):1183-1187.
20. Costenbader K.H., et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007, 56(4):1251-1262.
21. Bernier M.O., et al. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum. 2009, 61(4):476-481.
22. Andrade R.M., et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007, 56(2):622-630.
23. Voulgari P.V., et al. Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. Lupus 2002, 11(11):722-729.
24. Ward M.M., Studenski S. Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations. J. Rheumatol. 1990, 17(2):220-224.
25. Garcia M.A., et al. Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus 2005, 14(12):938-946.
26. Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989, 68(3):141-150.
27. Pistiner M., et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin. Arthritis Rheum. 1991, 21(1):55-64.
28. Reveille J.D., Bartolucci A., Alarcon G.S. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum. 1990, 33(1):37-48.
29. Prete P.E., et al. Systemic lupus erythematosus in men: a retrospective analysis in a Veterans Administration Healthcare System population. J. Clin. Rheumatol. 2001, 7(3):142-150.
30. Chang D.M., et al. The clinical features and prognosis of male lupus in Taiwan. Lupus 1998, 7(7):462-468.
31. Buyon J.P., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 2005, 142(12 Pt 1):953-962.
32. Arden N.K., et al. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994, 3(1):11-13.
33. Mok C.C., et al. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand. J. Rheumatol. 1998, 27(5):342-346.
34. Sanchez-Guerrero J., et al. Effect of hormone replacement therapy (HRT) on disease activity in postmenopausal patients with SLE. A two-year follow-up clinical trial [Abstract]. Arthritis Rheum. 2001, 44.
35. Petri M., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 2005, 353(24):2550-2558.
36. Crosbie D., et al. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst. Rev. 2007, 4. CD005114.
37. Petri M.A., et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004, 50(9):2858-2868.
38. Alvarez-Nemegyei J., et al. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998, 7(6):414-419.
39. Mintz G., et al. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J. Rheumatol. 1986, 13(4):732-739.
40. Nossent H.C., Swaak T.J. Systemic lupus erythematosus. VI. Analysis of the interrelationship with pregnancy. J. Rheumatol. 1990, 17(6):771-776.
41. Petri M., Howard D., Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 1991, 34(12):1538-1545.
42. Lockshin M.D. Does lupus flare during pregnancy?. Lupus 1993, 2(1):1-2.
43. Buyon J.P., et al. Favorable prognosis in a large, prospective multicenter study of lupus pregnancies. Arthritis Rheum. 2011, 63(Suppl. 10).
44. Clowse M.E., et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005, 52(2):514-521.
45. Liu J., et al. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. J. Matern. Fetal Neonatal. Med. 2012, 25(3):261-266.
46. Guballa N., et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2000, 43(3):550-556.
47. Hughes T., et al. Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann. Rheum. Dis. 2012, 71(5):694-699.
48. Webb R., et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann. Rheum. Dis. 2012, 70(1):151-156.
49. Chitnis S., et al. The role of X-chromosome inactivation in female predisposition to autoimmunity. Arthritis Res. 2000, 2(5):399-406.
50. Gregersen P.K., et al. Increased X-inactivation skewing in SLE?. Immunol. Today 1999, 20(3):152. (author reply 153).
51. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. J. Autoimmun. 2009, 33(1):3-11.
52. Jacob C.O., et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(15):6256-6261.
53. Kaufman K.M., et al. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann. Rheum. Dis. 2013, 72(3):437-444.
54. Subramanian S., et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(26):9970-9975.
55. Zhao S., Long H., Lu Q. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin. Rev. Allergy Immunol. 2010, 39(1):3-9.
56. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 2007, 8(5):457-462.
57. Lu Q., et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 2007, 179(9):6352-6358.
58. Sawalha A.H., et al. Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity. J. Autoimmun. 2012, 38(2-3):J216-J222.
59. Dillon S., et al. Klinefelter's syndrome (47, XXY) among men with systemic lupus erythematosus. Acta Paediatr. 2011, 100(6):819-823.
60. Scofield R.H., et al. Klinefelter's syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008, 58(8):2511-2517.
61. Goemaere S., et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J. Rheumatol. 1990, 17(12):1620-1622.
62. Myasoedova E., et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010, 62(6):1576-1582.
63. Brennan P., et al. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin. Arthritis Rheum. 1997, 26(6):817-823.
64. Karlson E.W., et al. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum. 2004, 50(11):3458-3467.
65. Nelson J.L., Ostensen M. Pregnancy and rheumatoid arthritis. Rheum. Dis. Clin. North Am. 1997, 23(1):195-212.
66. Silman A., Kay A., Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum. 1992, 35(2):152-155.
67. Walitt B., et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum. 2008, 59(3):302-310.
68. Karlson E.W., et al. A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis. Arthritis Res. Ther. 2009, 11(3):R97.
69. Cutolo M. Androgens in rheumatoid arthritis: when are they effectors?. Arthritis Res. Ther. 2009, 11(5):126.
70. Heliovaara M., et al. Smoking and risk of rheumatoid arthritis. J. Rheumatol. 1993, 20(11):1830-1835.
71. Stolt P., et al. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann. Rheum. Dis. 2005, 64(4):582-586.
72. Uhlig T., Hagen K.B., Kvien T.K. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J. Rheumatol. 1999, 26(1):47-54.
73. Forslind K., et al. Sex: a major predictor of remission in early rheumatoid arthritis?. Ann. Rheum. Dis. 2007, 66(1):46-52.
74. Iikuni N., et al. The influence of sex on patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol. 2009, 36(3):508-511.
75. Jawaheer D., Messing S., Reed G., Ranganath V.K., Kremer J.M., Louie J.S., Khanna D., Greenberg J.D., Furst D.E. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012, 64(12):1811-1818.
76. Jawaheer D., et al. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter?. J. Rheumatol. 2010, 37(12):2475-2485.
77. Makinen H., Hannonen P., Sokka T. Sex: a major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis?. Ann. Rheum. Dis. 2008, 67(7):1052-1053.
78. Jawaheer D., Olsen J., Hetland M.L. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis - results from the DANBIO registry. J. Rheumatol. 2012, 39(1):46-53.
79. Sokka T., et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res. Ther. 2009, 11(1):R7.
80. Lesuis N., et al. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012, 10:82.
81. D'Elia H.F., et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J. Rheumatol. 2003, 30(7):1456-1463.
82. Hall G.M., et al. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53(2):112-116.
83. van den Brink H.R., et al. Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis. Ann. Rheum. Dis. 1993, 52(12):862-865.
84. Booji A., et al. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann. Rheum. Dis. 1996, 55(11):811-815.
85. Barrett J.H., et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 1999, 42(6):1219-1227.
86. Kovacs W.J., Olsen N.J. Sexual dimorphism of RA manifestations: genes, hormones and behavior. Nat. Rev. Rheumatol. 2011, 7(5):307-310.
87. Burkhardt J., et al. Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis. J. Rheumatol. 2009, 36(10):2149-2157.
88. Somers E.C., et al. Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter?. Ann. Rheum. Dis. 2013, 72(4):525-529.
89. Hochberg M.C. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum. 1985, 28(1):80-86.
90. McCarty D.J., et al. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 1995, 38(9):1260-1270.
91. Naleway A.L., et al. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 2005, 14(10):862-866.
92. Feldman C.H., et al. Epidemiology and Sociodemographics of Systemic Lupus Erythematosus and Lupus Nephritis among U.S. Adults with Medicaid Coverage, 2000-2004. Arthritis Rheum. 2013, 65(3):753-763.
93. Gabriel S.E., Crowson C.S., O'Fallon W.M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum. 1999, 42(3):415-420.
94. Pedersen J.K., Svendsen A.J., Horslev-Petersen K. Incidence of rheumatoid arthritis in the southern part of Denmark from 1995 to 2001. Open Rheumatol. J. 2007, 1:18-23.